Main Article Content
Oxprenolol and ventricular ectopic activity of the heart
Abstract
Oxprenolol (Trasicor), a beta-receptor blocking agent widely used in angina pectoris, was evaluated for its possible arrhythmogenic or antidysrhythmic effects. In a, randomised double-blind within-patient trial, 44 physically active postmyocardial infarction patients completed the trial. Ventricular ectopic activity was evaluated on a magnetic tape and recorded over 7-hour periods while the patients were active at work. No deleterious effects were noted in 73%, an increase in electrical stability was noted in 23% and only one patient was evaluated as being worse while on the drug.
S. Afr. Med. J., 48, 1073 (1974)
S. Afr. Med. J., 48, 1073 (1974)